Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10862259 | 0.84 | HTT (0.38) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL329004 | 0.77 | ALDH1A1 (0.44) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL991441 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL8389921 | 0.74 | NPC1 (0.36) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL4633204 | 0.66 | NPC1 (0.48) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL21419520 | 0.66 | HTT (0.39) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL12874162 | 0.64 | GPR35 (0.37) | — | |
| SCHEMBL12704406 | 0.64 | GPR35 (0.37) | — | |
| SCHEMBL22654106 | 0.63 | — | — | |
| SCHEMBL4824479 | 0.62 | HTT (0.37) | NPC1HPGDMAPK1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | NPC1 3538/4885HPGD 306/4885MAPK1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.